Downloaded 13 times
![Generic drugs
The CEO of Cipla reached the government
of Indira Gandhi to change India's patent
laws to eliminate patents that directly
covered drugs, and instead to allow only
patents that covered methods to make
drugs.[43] so that Cipla could go ahead and
produce as many low-priced generic drugs
for the poor as possible.
In the late 1960s, Cipla began
manufacturing a new, patented
drug, propranolol, without the
permission of the drug's patent
holder, Imperial Chemical
Industries (ICI), which protested
to the Indian government.
Since then Cipla has also produced a
low-cost drug to treat HIV and
expanded operations into several
developing countries, including African
nations, where most HIV and poor
patients existed at one time. But the
changes made led to criticism of both
India's patent laws and Cipla.](https://image.slidesharecdn.com/cipla-200908065921/85/Cipla-10-320.jpg)
More Related Content
Cipla
- 1. MPC: 7066 –chemistry Name : Omer Shaikh caring for life Cipla
- 2. Content About Cipla History Ceo of Cipla Products and services Operations Shareholding Awards and recognition Generic drugs Mission statement Industry analysis . .
- 3. About Cipla Cipla Limitedis an Indian multinational pharmaceutical company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression other medical conditions. Established in 1935, Cipla is a global pharmaceutical company focused on responsible and sustainable growth through deep & wide portfolio and strong customer relationships across our home markets of India, South Africa, US and other key regulated and emerging markets. the strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 46 manufacturing facilities around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India and 3rd largest in the pharma private market in South Africa
- 4. Yusuf Ahmed Khwaja AbdulHamied History It was founded by Khwaja Abdul Hamied as 'The Chemical, Industrial & Pharmaceutical Laboratories' in 1935 in Mumbai. The name of the Company was changed to 'Cipla Limited' on 20 July 1984. In the year 1985, US FDA approved the company's bulk drug manufacturing facilities. Led by the founder's son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world. In 1995, Cipla launched Deferiprone, the world's first oral iron chelator. In 2001, Cipla offered medicines (antiretroviral) for HIV treatment at a fractional cost (less than $350 per year per patient).
- 5. Products and services Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products, including Escitalopram (anti-depressant), Lamivudine and Fluticasone propionate. They are the world's largest manufacturer of antiretroviral drugs. In July 2020, the company announced the introduction of Gilead Sciences' Remdesivir under the brand name CIPREMI in India after reaching an voluntary licensing agreement with parent company and DCGI approval for "restricted emergency use" in COVID-19 treatment of critical confirmed patients
- 6. Ceo of Cipla Mr.Umang Vohra Managing Director & Global Chief Executive Officer Mr. Umang Vohra joined Cipla Limited in 2015 and has been the MD & GCEO of the Company since September 2016. After gaining degrees in engineering, marketing and finance, Mr. Vohra worked with Eicher Motors, PepsiCo and Dr Reddy’s Laboratories. Through his previous roles in India and the US, he has built a distinguished career spanning almost two decades with deep understanding and experience of various aspects of the global pharmaceutical business.
- 7. Operation . . . Cipla has 34manufacturing units in 8 locations across India and a presence in over 80 countries. Exports accounted for 48% ₹4,948 crore (equivalent to ₹68 billion or US$950 million in 2019) of its revenue for FY 2013–14. Cipla spent INR 517 cr. (5.4% of revenue) in FY 2013–14 on R&D activities. The primary focus areas for R&D were development of new formulations, drug- delivery systems and APIs (active pharmaceutical ingredients). Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know- how transfer, support, and plant supply.
- 8. Shareholding . . 8% 18% 18% 9% 19% 0%0% 28% Revenue Net incomeDiluted EPS Net profit margin Operating income Net change in cash Cash on hand Cost of revenue 0.00% 200.00% 400.00% 600.00% 800.00% 1000.00%1200.00%1400.00% Chart Title Promoter Group Foreign Institutional Investors (FII) Individual shareholders Insurance companies Private Corporate Bodies Mutual Funds and UTI NRI/FCB/Others GDRs Total
- 9. Awards and recognition .. . In 2012, Cipla received the Thomson Reuters India Innovation Award. Cipla won Dun & Bradstreet American Express Corporate Awards in 2006. In 2007, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies. In 1980, Cipla won Chemexcil Award for Excellence for exports
- 10. Generic drugs TheCEO of Cipla reached the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs, and instead to allow only patents that covered methods to make drugs.[43] so that Cipla could go ahead and produce as many low-priced generic drugs for the poor as possible. In the late 1960s, Cipla began manufacturing a new, patented drug, propranolol, without the permission of the drug's patent holder, Imperial Chemical Industries (ICI), which protested to the Indian government. Since then Cipla has also produced a low-cost drug to treat HIV and expanded operations into several developing countries, including African nations, where most HIV and poor patients existed at one time. But the changes made led to criticism of both India's patent laws and Cipla.
- 11. Mission statement Cipla missionis to be a leading global health care company which uses technology and innovation to meet everyday needs of all patients.
- 12. Industry analysis 04 . 05 06 . 01 . 02 03 Inthe domestic market, Cipla continued to maintain its leadership position in various therapeutic segments including respiratory, anti-virals, gynecology and urology for the period 2012-13. The Company’s domestic business constitutes ~45 % of its total revenues. Currently, it commands 5.7 % market share (as per AIOCD AWACS) in domestic pharmaceutical space. Its domestic business has grown at a CAGR of 10 % over the last five years. The growth in domestic revenues was largely on account of growth in anti- asthma, anti-biotics and cardiovascular therapy segments
- 13. 0 20000 4000060000 80000 100000 120000 140000 160000 180000 Sun Pharma Divis Labs Dr Reddys Labs Cipla Aurobindo Pharm Torrent Pharma Lupin Cadila Health Abbott India Alkem Lab GlaxoSmithKline Last Price Market Cap. (Rs. cr.) Sales Turnover Net Profit Total Assets
- 14.
- 15.